Sean Laaman
Stock Analyst at Morgan Stanley
(2.60)
# 2,241
Out of 4,969 analysts
8
Total ratings
85.71%
Success rate
10.33%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Overweight | $85 → $90 | $61.58 | +46.15% | 2 | Aug 18, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $48 → $46 | $37.18 | +23.72% | 1 | Jul 29, 2025 | |
| AXSM Axsome Therapeutics | Assumes: Overweight | $190 | $123.47 | +53.88% | 1 | Jul 3, 2025 | |
| CERT Certara | Assumes: Equal-Weight | $16 | $10.66 | +50.09% | 1 | Jul 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $313 → $330 | $332.04 | -0.61% | 1 | Jun 27, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $2.59 | -42.08% | 1 | Mar 7, 2025 | |
| RMD ResMed | Upgrades: Overweight | $169 | $270.99 | -37.64% | 1 | Oct 27, 2023 |
Disc Medicine
Aug 18, 2025
Maintains: Overweight
Price Target: $85 → $90
Current: $61.58
Upside: +46.15%
Exelixis
Jul 29, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $37.18
Upside: +23.72%
Axsome Therapeutics
Jul 3, 2025
Assumes: Overweight
Price Target: $190
Current: $123.47
Upside: +53.88%
Certara
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $16
Current: $10.66
Upside: +50.09%
BeOne Medicines AG
Jun 27, 2025
Maintains: Overweight
Price Target: $313 → $330
Current: $332.04
Upside: -0.61%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.59
Upside: -42.08%
ResMed
Oct 27, 2023
Upgrades: Overweight
Price Target: $169
Current: $270.99
Upside: -37.64%